Skip to main content
TipRanks
Go Ultimate75% OFF

Voyager Therapeutics (VT6) Q4 2024 Earnings Report

5 Followers

DE:VT6 Q4 2024 EPS Results

Actual EPS
-EUR 0.53
Consensus EPS
-EUR 0.33
Beat/Miss
Missed by -EUR 0.20
One Year Ago EPS
EUR 1.13

DE:VT6 Q4 2024 Revenue Results

Actual Revenue
EUR 5.67M
Expected Revenue
EUR 14.99M
Beat/Miss
Missed by -EUR 9.31M
YoY Revenue Growth
-93.03%

Earnings Announcement Details

Quarter
Q4 2024
Date
03/11/2025
Time
After Close
Conference Call
Tuesday, March 11, 2025
DE:VT6 Upcoming Earnings

Voyager Therapeutics's next earnings date is estimated for March 9, 2027, based on past reporting schedules.

Q4 2024 Earnings Call Audio

DE:VT6 Q4 2024 Earnings Call
0:00 / 0:00

Q4 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2024 Earnings Call Summary

Q4 2024
Earnings Call Date:Mar 11, 2025|% Change Since:-61.10%|
Earnings Call Sentiment|Positive

The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.

Company Guidance

During the Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call, the company provided several key metrics and updates about their progress and future plans. Voyager reported $332 million in cash as of the end of 2024 and highlighted potential future milestone payments totaling $8.2 billion, emphasizing the significance of their partnerships as a source of non-dilutive revenue. The company is advancing its tau silencing gene therapy, VY1706, into IND-enabling studies, targeting IND submission in 2026, with promising non-human primate study results showing 50% to 73% knockdown of tau messenger RNA across the brain. Additionally, the anti-tau antibody, VY7523, showed favorable results in a single ascending dose study, with a CSF to serum ratio of 0.3%. Voyager expects initial tau PET data from a multiple ascending dose study in Alzheimer's patients in the second half of 2026. They also noted their $2.9 billion in developmental milestones and guidance extending their cash runway to mid-2027.

  • Strong Cash Position and Potential Milestone PaymentsVoyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.
  • Advancements in Tau Silencing ProgramThe tau silencing gene therapy program, VY1706, moved forward into IND-enabling studies, showing 50% to 73% knockdown of tau messenger RNA in non-human primate studies.
  • Positive Results for Anti-Tau Antibody VY7523VY7523 performed well in a single ascending dose study with no serious adverse events, showing dose-proportional pharmacokinetics and a CSF to serum ratio of 0.3%.
  • Promising External Data Supporting Anti-Tau StrategiesUCB's bepranemab demonstrated impact on tau accumulation, and further data from Merck and other companies are anticipated, which may support the potential of tau-targeted therapies.
  • Progress in Partnered Programs with NeurocrineTwo programs with Neurocrine are expected to enter the clinic or have an IND filed this year, indicating positive collaboration progress.

DE:VT6 Earnings History

DE:VT6 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 09, 20272026 (Q4)-0.31--0.42――
Nov 05, 20262026 (Q3)-0.38-0.36-0.4214.89% (+0.06)
Aug 06, 20262026 (Q2)-0.44-0.36-0.5229.82% (+0.15)
May 07, 20262026 (Q1)-0.50-0.42-0.4811.32% (+0.05)
Mar 09, 20262025 (Q4)-0.46-0.42-0.5322.03% (+0.12)
Nov 10, 20252025 (Q3)-0.47-0.42-0.14-193.75% (-0.28)
Aug 06, 20252025 (Q2)-0.48-0.52-0.16-216.67% (-0.35)
May 06, 20252025 (Q1)-0.41-0.48-0.18-165.00% (-0.30)
Mar 11, 20252024 (Q4)-0.33-0.531.13-147.20% (-1.66)
Nov 12, 20242024 (Q3)-0.40-0.14-0.5372.88% (+0.39)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed